Pipeline / Products

Patents:

Patent technology

• Europe: issued under No. EP 2170941 28 December 2012
• China: issued under No. ZL 200880021020.X on 1 May 2013
• United States: issued under No. US 8,492,342 July 23, 2013
• Australia: issued under No. AU 2008277350 December 5 ,2013
• Japan: issued under No. JP 5393661 October 25, 2013
• Canada: application CA 2691406 patent pending

Patent Products

• European Patent Application 15176174.9 No. - 1403. Date: 09/23/15

ElyssaMed® develops multiple drug candidates targeting cancer based on a novel technological platform; its lead product EM-03 is developed to treat non-small cell lung cancer.

• 1st in class
• Combination of selected proprietary immunogenic peptides targeting a specific lung tumor associated antigen.
• MOA: this antigen overcome tumor escape from the immune system by using a novel process mechanism independent of TAP/ Proteasome pathway/
• Route of administration: Intra dermal injection
• Used in combination with a marketed vaccine adjuvant
• API & DP produced by CMO FDA / EMA approved

For decades, lung cancer has been the leading cause of cancer death in the world. Despite the possibilities of surgery and chemo- or radio-therapy treatments, only 15% of patients are still alive two years after diagnosis. Therefore lung cancer represents both a medical challenge and a socio-economic problem at the forefront of public health in Europe and the United States. ElyssaMed® will primarily target the cancer drug market. This market reached 60 billion Euro in 2012, including 6 billion in France. Its growth, estimated at 10.8% per year, is twice as fast as that of the entire pharmaceutical market.

The first cancer that will be targeted by the ElyssaMed® technology is the non-small cell lung cancer which account for 80% of lung cancers. However, the team's research studies have shown that other cancers could be targeted by the vaccine including medullary thyroid cancers (MTC), neuroendocrine tumors (NET) and small cell lung cancers (SCLC) as well as all tumors that express PPCT.

The latter pathologies include those that are classified as rare (orphan) diseases for which a facilitated and accelerated development of new treatments is permitted.